DISCOUNT OPTIONSSCHEIN - AMGEN | Real-time Bid/Ask 14:54:06 09/05/2024 BST | ||
| 2.51 EUR / 2.63 EUR | +7.08% |
|
| Current month | +51.90% | ||
| 1 month | +36.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 2.32 | -3.33% | 0 |
| 08/05/24 | 2.4 | +3.45% | 0 |
| 07/05/24 | 2.32 | -32.56% | 0 |
| 06/05/24 | 3.44 | -11.11% | 0 |
| 03/05/24 | 3.87 | +133.13% | 0 |
Delayed Quote Börse Stuttgart
Last update May 09, 2024 at 09:58 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME66P3 |
| ISIN | DE000ME66P38 |
| Date issued | 02/01/2024 |
| Strike | 360 $ |
| Maturity | 20/09/2024 (134 Days) |
| Parity | 1 : 1 |
| Emission price | 1.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.53 € |
|---|---|
| Lowest since issue | 1.34 € |
| Spread | 0.18 € |
| Spread % | 6.82% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.3
USD
Average target price
313.3
USD
Spread / Average Target
+1.95%
- Stock Market
- Certificates
- Certificat
